Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India | Korea
Approved Indications: None
Known Adverse Events: None
Company: Yuekang Pharmaceutical Group Co., Ltd./Hefei Xinfeng Technology Development Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20132310 |
CTR20132310 | N/A |
Completed |
Klebsiella Infections|Cystitis|Serratia Infections|Pseudomonas Infections|Urinary Tract Infections|Escherichia coli Infections|Proteus Infections|Urethritis |
2013-11-01 |
2025-04-29 |
Patient Enrollment|Treatments |